Nordic Capital related stories
All articles and analysis
Medtech moves into private equity’s sweet spotLower valuations, corporate carve-outs and resilience to AI disruption are opening up medtech to buyout firms after years of limited access.
Regulatory pressures, AI opportunities draw PE to life sciences software: 8 dealsArdian, Bregal Sagemount, Riverside and Thoma Bravo are among the PE dealmakers targeting investments in the life sciences software market.
Where’s the ROI in AI?In theory, artificial intelligence should slash costs and ramp up productivity at the GP level, but achieving a return on that investment is proving to be a slow process.
Nordic Capital-backed LEO Pharma to acquire dersimelagon rights from Bain-owned Tanabe for $435mLEO Pharma, which the release describes as a global leader in medical dermatology, serves close to 100 million patients in more than 70 countries annually.
Nordic Capital to carve out BWXT's medical business in $800m transactionNordic expects to scale BWXT's capabilties and market presense in radiopharmaceuticals.
Side Letter: Secondaries déjà vuIn today's edition, Secondaries volumes break another record; Europe amasses a war chest (quite literally); Astorg is racking up exits.
- Nordic Capital to sell life sciences software provider ArisGlobal
ArisGlobal’s client base includes many pharmaceutical and biotech companies as well as regulatory authorities.
Astorg’s Judith Charpentier: Mid-market focus will maximize exit choicesWhile the valuation gap is ‘slightly reducing,’ the volatile macro backdrop makes exit optionality even more important, Astorg’s co-managing partner told PE Hub.
3 reasons PE is targeting European water treatment'The scale of investment required across water and wastewater infrastructure is significant, while the sector faces constraints in terms of skilled labor, specialist equipment and engineering expertise,' Nordic Capital's Andreas Näsvik told PE Hub.
How a decade of pharma digitalization drove Nordic's $8.9bn sale of Clario to Thermo Scientific'The sale to Thermo Fisher Scientific was the single biggest full exit in private equity globally announced last year,' Daniel Berglund, partner and head of healthcare at Nordic Capital, told PE Hub.